Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

From the origin of NASH to the future of metabolic fatty liver disease
Andreas Geier, Dina Tiniakos, Helmut Denk, et al.
Gut (2021) Vol. 70, Iss. 8, pp. 1570-1579
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Oriol Juanola, Sebastián Martínez‐López, Rubén Francés, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 10, pp. 5227-5227
Open Access | Times Cited: 192
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 191
Current therapies and new developments in NASH
Jean‐François Dufour, Quentin M. Anstee, Elisabetta Bugianesi, et al.
Gut (2022) Vol. 71, Iss. 10, pp. 2123-2134
Open Access | Times Cited: 146
SLC7A11-ROS/αKG-AMPK axis regulates liver inflammation through mitophagy and impairs liver fibrosis and NASH progression
Tingting Lv, Xiude Fan, Chang He, et al.
Redox Biology (2024) Vol. 72, pp. 103159-103159
Open Access | Times Cited: 14
AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion
Jae-Jun Kim, Simone N. T. Kurial, Pervinder K. Choksi, et al.
Nature Biotechnology (2025)
Open Access | Times Cited: 1
Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut–liver axis
Hui Han, Yi Jiang, Mengyu Wang, et al.
Critical Reviews in Food Science and Nutrition (2021) Vol. 63, Iss. 12, pp. 1689-1706
Closed Access | Times Cited: 87
Metabolic dysfunction–associated fatty liver disease and the risk of 24 specific cancers
Zhenqiu Liu, Chunqing Lin, Chen Suo, et al.
Metabolism (2021) Vol. 127, pp. 154955-154955
Closed Access | Times Cited: 68
Bile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease
Rui Xue, Lianyong Su, Shengyi Lai, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 2806-2806
Open Access | Times Cited: 57
Chinese herbal medicines: The modulator of nonalcoholic fatty liver disease targeting oxidative stress
Pin Gong, Hui Long, Yuxi Guo, et al.
Journal of Ethnopharmacology (2023) Vol. 318, pp. 116927-116927
Closed Access | Times Cited: 30
Berberine prevents NAFLD and HCC by modulating metabolic disorders
Xinyue Lin, Jilei Zhang, Yajun Chu, et al.
Pharmacology & Therapeutics (2024) Vol. 254, pp. 108593-108593
Closed Access | Times Cited: 11
Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications
Doris Ogresta, Anna Mrzljak, Maja Cigrovski Berković, et al.
Journal of Clinical and Translational Hepatology (2022) Vol. 10, Iss. 2, pp. 339-355
Open Access | Times Cited: 30
Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective
Swasthika Gurjar, R. A., Raghavendra Upadhya, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access
Remote limb ischemic conditioning alleviates steatohepatitis via extracellular vesicle-mediated muscle-liver crosstalk
Yichao Zhao, Ling Gao, Jianqing Chen, et al.
Cell Metabolism (2025)
Closed Access
Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization
David T. Fetzer, Iván M. Rosado-Méndez, Michael H. Wang, et al.
Radiology (2022) Vol. 305, Iss. 2, pp. 265-276
Open Access | Times Cited: 24
Therapeutic modulation of the liver immune microenvironment
Herbert Tilg, Timon E. Adolph, Frank Tacke
Hepatology (2023)
Closed Access | Times Cited: 15
Diagnostic Challenges during Inflammation and Cancer: Current Biomarkers and Future Perspectives in Navigating through the Minefield of Reactive versus Dysplastic and Cancerous Lesions in the Digestive System
Ioannis S. Pateras, Ana Igea, Ilias P. Nikas, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1251-1251
Open Access | Times Cited: 4
PNPLA3fatty liver allele was fixed in Neanderthals and segregates neutrally in humans
Andreas Geier, Jonas Trost, Ke Wang, et al.
Gut (2024) Vol. 73, Iss. 6, pp. 1008-1014
Closed Access | Times Cited: 4
Ethanol extract of Polygonatum cyrtonema Hua mitigates non-alcoholic steatohepatitis in mice
Dongliang Chen, Yue Shen, Fang Huang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Evolutionäre Aspekte der mit metabolischer Dysfunktion assoziierten steatotischen Lebererkrankung (MASLD)
Andreas Geier, Stephan Schiffels, Marcin Krawczyk
Deleted Journal (2025)
Closed Access
Alterations of Gut Microbiome and Serum Metabolome in Coronary Artery Disease Patients Complicated With Non-alcoholic Fatty Liver Disease Are Associated With Adverse Cardiovascular Outcomes
Xiaomin Hu, Ruilin Zhou, Hanyu Li, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 8
Open Access | Times Cited: 21
Comparison of cardiovascular mortality between MAFLD and NAFLD: A cohort study
Tae Kyung Yoo, Mi Yeon Lee, Seong Hwan Kim, et al.
Nutrition Metabolism and Cardiovascular Diseases (2023) Vol. 33, Iss. 5, pp. 947-955
Open Access | Times Cited: 12
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Qingfu Dong, Haolin Bao, Jiangang Wang, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 11
Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease
Fan Zhang, Yan Han, Yunfei Wu, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 3
Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung)“ zur S2k-Leitlinie „Nicht-alkoholische Fettlebererkrankung“ (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)
Elke Roeb, Ali Canbay, Heike Bantel, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 07, pp. 1077-1087
Closed Access | Times Cited: 3
Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse
Sangam Rajak, Pratima Gupta, Baby Anjum, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1868, Iss. 4, pp. 166319-166319
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top